[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 76 of about 76
1. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T: Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer; 2009 May 1;115(9):1867-74
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
  • BACKGROUND: : The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS).
  • METHODS: : Mifepristone (RU-486; 200 mg orally) was given daily to patients with progesterone receptor-positive advanced or recurrent endometrioid adenocarcinoma or LGESS.
  • Among the patients who had stable disease, 2 women had endometrioid endometrial cancer, and 1 woman had LGESS.
  • CONCLUSIONS: : Single-agent mifepristone used in the treatment of recurrent endometrioid adenocarcinoma or LGESS resulted in a stable disease rate of 25%.
  • The authors concluded that further research into the best mode of application for mifepristone in the treatment of endometrial cancer is needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Endometrioid / drug therapy. Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241422.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098258
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down


2. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Endometrial cancer is predominately a postmenopausal disease.
  • Endometrial cancer in women of childbearing age is relatively unusual.
  • Endometrial cancer is typically treated with hysterectomy.
  • After the development of endometrial cancer, successful pregnancy is rare.
  • We present a case of recurrent stage I endometrial adenocarcinoma in a 35-year-old woman.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • Recurrent endometrial adenocarcinoma was documented using hysteroscopy and direct endometrial biopsy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


3. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR, Gynecologic Oncology Group study: Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer; 2006 Nov 1;107(9):2197-205
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
  • BACKGROUND: Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer.
  • METHODS: The authors retrospectively reviewed data from 169 black women and 982 white women with International Federation of Gynecologic Oncology (FIGO) Stage III, Stage IV, or recurrent endometrial carcinoma who were participants in 1 of 4 Gynecologic Oncology Group randomized treatment trials of doxorubicin alone or combined with paclitaxel and/or cisplatin.
  • CONCLUSIONS: The data from a large group of women with advanced/recurrent endometrial cancer suggested that a racial disparity in survival persists, despite the finding that black women and white women received similar treatment.
  • Although the causes of racial disparity in endometrial cancer remain to be elucidated, socioeconomic, biologic, and cultural factors should be investigated to identify the etiologic origins of this multifactorial healthcare problem.
  • [MeSH-major] Adenocarcinoma / ethnology. African Americans. Endometrial Neoplasms / ethnology. European Continental Ancestry Group. Neoplasm Recurrence, Local / ethnology

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001661.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH: Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol; 2007 Jan;62(1):28-34; discussion 35-6
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis.
  • AIM: To evaluate patterns of disease and identify factors predicting outcome in patients presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • MATERIALS AND METHODS: A retrospective review was performed of the imaging and clinical data in 86 patients (median age 66 years, range 42-88 years) presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • RESULTS: Following primary surgery recurrent disease occurred within 2 years in 64% and within 3 years in 87%.
  • Significant predictors of poor outcome in recurrent disease are multiple sites of disease and liver and splenic metastases.
  • [MeSH-major] Adenocarcinoma / radiography. Endometrial Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145260.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA: Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer; 2006 Jul 1;107(1):90-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome.
  • BACKGROUND: Epithelial membrane protein 2 (EMP2) is an estrus-regulated tetraspan protein that is required for endometrial competence in blastocyst implantation.
  • These features suggest that EMP2 may contribute to neoplastic traits of endometrial cancer.
  • The objective of this study was to determine the prevalence of EMP2 expression in endometrial neoplasms and its clinical significance.
  • METHODS: EMP2 immunophenotype, histologic diagnosis, grade, the presence of lymphovascular invasion, disease stage, and clinical follow-up were determined for 99 endometrial cancers.
  • RESULTS: Significant EMP2 expression (EMP2 positive) was observed in 12 of 99 cancers (9 endometrioid [6 International Federation of Gynecology and Obstetrics Grade 3], 1 serous, 1 mixed endometrioid and serous, and 1 mixed endometrioid and clear cell), and weak EMP2 expression was observed in 11 cancers.
  • EMP2-positive tumors were more likely than others to be myometrium invasive, high stage, and recurrent, persistent, or fatal.
  • CONCLUSIONS: EMP2 expression is a feature of some prognostically unfavorable endometrial cancers.
  • Its utility for clinical decision making and its biologic role in endometrial cancer deserves further study in a larger series of patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16736513.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16042-29; United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / HD048540; United States / NCATS NIH HHS / TR / UL1 TR000124; United States / NICHD NIH HHS / HD / HD40376; United States / NCI NIH HHS / CA / T32 CA009120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EMP2 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


6. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T: Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG; 2005 Mar;112(3):317-20
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of fertility-preserving treatment in young women with endometrial carcinomas.
  • OBJECTIVE: To evaluate the outcome of conservative treatment of young women with endometrial cancer.
  • POPULATION: Twelve women with endometrial cancer, FIGO IA estimated by MRI under 35 years.
  • METHODS: Patients were treated with medroxyprogestreone acetate (400-600 mg/day) for 6-10 months, with endometrial curettage performed every four weeks.
  • Eight of nine cases receiving long term follow up (over 30 months) developed recurrent disease, with four opting for hysterectomy.
  • CONCLUSION: Conservative therapy is feasible in carefully selected young women with endometrial cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Carcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Infertility, Female / prevention & control. Medroxyprogesterone Acetate / administration & dosage. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Cohort Studies. Combined Modality Therapy / methods. Dilatation and Curettage / methods. Endometrium / pathology. Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / etiology. Pregnancy. Pregnancy Outcome. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713146.001).
  • [ISSN] 1470-0328
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


7. Samuelson E, Hedberg C, Nilsson S, Behboudi A: Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats. Endocr Relat Cancer; 2009 Mar;16(1):99-111
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats.
  • Female rats of the BDII/Han inbred strain are prone to spontaneously develop endometrial carcinomas (EC) that in cell biology and pathogenesis are very similar to those of human.
  • Human EC are classified into two major groups: Type I displays endometroid histology, is hormone-dependent, and characterized by frequent microsatellite instability and PTEN, K-RAS, and CTNNB1 (beta-Catenin) mutations; Type II shows non-endometrioid histology, is hormone-unrelated, displays recurrent TP53 mutation, CDKN2A (P16) inactivation, over-expression of ERBB2 (Her2/neu), and reduced CDH1 (Cadherin 1 or E-Cadherin) expression.
  • The EC developed in BDII rats can be related to type I tumors, since they are hormone-related and histologically from endometrioid type.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / genetics. Endometrial Neoplasms / classification. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Alleles. Animals. Cadherins / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Endometrium / physiology. Female. Glycoproteins / genetics. Interferon Regulatory Factor-1 / genetics. Male. Mutation. PTEN Phosphohydrolase / genetics. Rats. Rats, Inbred Strains. Receptor, ErbB-2. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / genetics. beta Catenin / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075038.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ctnnb1 protein, rat; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Erbb2 protein, rat; 0 / Glycoproteins; 0 / Interferon Regulatory Factor-1; 0 / Irf1 protein, rat; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.1.3.48 / Pten protein, rat; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


8. Akram T, Maseelall P, Fanning J: Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol; 2005 May;192(5):1365-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
  • OBJECTIVE: The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer.
  • STUDY DESIGN: This was a retrospective review of 18 consecutive patients with advanced (stage 4) or recurrent endometrial adenocarcinoma that had been treated with outpatient carboplatin and taxol.
  • CONCLUSION: Carboplatin and taxol for the treatment of advanced or recurrent endometrial cancer appear to be active regimens with minimal toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902110.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev; 2005;(4):CD003915
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
  • BACKGROUND: Endometrial adenocarcinoma is a common gynaecological cancer, but a comparatively small proportion of patients present with or develop recurrent or advanced disease.
  • OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma.
  • Only one trial showed a significant survival benefit from the addition of paclitaxel to combination chemotherapy, but this was at the expense of increased toxicity.
  • AUTHORS' CONCLUSIONS: The optimum cytotoxic drug regimen for advanced endometrial adenocarcinoma has still to be defined although our review suggests that it may contain paclitaxel or platinum.
  • These mainly North American and European trial populations represent a highly selected subgroup of the 10,000 women dying annually from this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;8:CD003915 [22895938.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(3):CD003915 [16034916.001]
  • (PMID = 16235346.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 109
  •  go-up   go-down


10. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev; 2005;(3):CD003915
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
  • BACKGROUND: Endometrial adenocarcinoma is a common gynaecological cancer, but a comparatively small proportion of patients present with or develop recurrent or advanced disease.
  • OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma.
  • Only one trial showed a significant survival benefit from the addition of paclitaxel to combination chemotherapy, but this was at the expense of increased toxicity.
  • There were no comparative trials of chemotherapy with endocrine therapy AUTHORS' CONCLUSIONS: The optimum cytotoxic drug regimen for advanced endometrial adenocarcinoma has still to be defined although our review suggests that it may contain paclitaxel or platinum.
  • These mainly North American and European trial populations represent a highly selected subgroup of the 10, 000 women dying annually from this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2005;(4):CD003915 [16235346.001]
  • (PMID = 16034916.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 109
  •  go-up   go-down


11. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol; 2008 Sep;199(3):e7-e10
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
  • Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician.
  • We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550023.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


12. Pectasides D, Pectasides E, Economopoulos T: Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev; 2007 Apr;33(2):177-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy in metastatic or recurrent endometrial cancer.
  • Endometrial cancer is one of the most common gynecologic malignancies.
  • In patients with advanced or recurrent endometrial cancer survival is greatly diminished.
  • Hormonal therapy and chemotherapy play a major role in the management of advanced or recurrent endometrial cancer.
  • The combination of cisplatin plus doxorubicin is the most commonly used regimen, but carboplatin plus paclitaxel represents an efficacious, low toxicity regimen in advanced or recurrent endometrial cancer.
  • At this time the focus of future research should be on the use of novel targeted agents, since it is unlikely that further significant advances could be made with chemotherapy and endocrine therapy. mTOR inhibitors represent a promising therapeutic strategy for endometrial cancer.
  • Anti-HER-2/neu targeted therapy might be a novel and attractive therapeutic option in patients with biologically aggressive variants (uterine serous papillary carcinoma, clear cell carcinoma) of endometrial cancer.
  • Research in better understanding the signal transduction pathways in endometrial carcinogenesis will allow the development of specific and selective molecularly targeted inhibitors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy


13. Michener CM, Peterson G, Kulp B, Webster KD, Markman M: Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol; 2005 Sep;131(9):581-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
  • PURPOSE: To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer.
  • METHODS: Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease.
  • CONCLUSIONS: The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma.
  • The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-57-S15-61 [9346224.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 2):78-83 [10190786.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):397-400 [8112651.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):283-5 [9625439.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1408-14 [8021731.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1021-9 [11181665.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72 [10985896.001]
  • [Cites] Am J Clin Oncol. 1993 Dec;16(6):494-6 [8256764.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):264-7 [2013451.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):52-7 [10873410.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • (PMID = 15959825.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Samuelson E, Levan K, Adamovic T, Levan G, Horvath G: Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet; 2008 Feb;181(1):25-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization.
  • In inbred BDII rats, which are genetically predisposed to endometrial adenocarcinomas (EAC), certain chromosome regions exhibit recurrent amplification in the tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Gene Amplification

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262049.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cyp1b1 protein, rat; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


15. Powell JL, Cunill ES, Gajewski WH, Novotny DB: Sarcoidosis mimicking recurrent endometrial cancer. Gynecol Oncol; 2005 Dec;99(3):770-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis mimicking recurrent endometrial cancer.
  • In patients with recurrent gynecologic cancer, liver and intrathoracic lesions should undergo a biopsy to rule in metastatic malignancy, as clinical findings and CAT scan results may represent other disease processes.
  • CASE: A 67 year old woman had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic lymphadenectomy, and peritoneal cytology in 2001 for Stage I B grade 1 adenocarcinoma of the endometrium.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Sarcoidosis / diagnosis

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168469.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Nordlander C, Samuelson E, Klinga-Levan K, Behboudi A: Recurrent chromosome 10 aberrations and Tp53 mutations in rat endometrial adenocarcinomas. Adv Exp Med Biol; 2008;617:519-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent chromosome 10 aberrations and Tp53 mutations in rat endometrial adenocarcinomas.
  • Endometrial adenocarcinoma (EAC) is the most common gynecologic malignancy, ranking fourth in incidence among tumors in women.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Mammalian / genetics. Endometrial Neoplasms / genetics. Mutation / genetics. Tumor Suppressor Protein p53 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497077.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS, Southwest Oncology Group: Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol; 2005 Mar;96(3):610-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
  • OBJECTIVES: To evaluate the response rate and progression free and overall survival of patients with advanced endometrial cancer treated with paclitaxel, carboplatin and amifostine.
  • METHODS: Forty-seven eligible patients (median age: 66; range 45-82) with bidimensionally measurable advanced, recurrent, or refractory endometrial cancer were treated with carboplatin (AUC = 6), paclitaxel (175 mg/M2) and amifostine (740 mg/M2) every 4 weeks for 6 cycles or until disease progression or unacceptable toxicity.
  • The regimen demonstrated significant activity in endometrial cancer, comparable to other multi-agent chemotherapy programs in terms of response rate and survival, and with a favorable toxicity profile.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721401.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03096; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA68183; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76462
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones RL, Blake P, Gabra H, Hall G, Gore ME, Kaye SB: A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol; 2009 Nov;20(11):1787-93
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
  • BACKGROUND: Platinum compounds, taxanes and anthracyclines provide the major effective drug classes in the treatment of advanced and recurrent endometrial cancer and carcinosarcoma.
  • PATIENTS AND METHODS: A total of 52 women with advanced or recurrent endometrial cancer and carcinosarcoma were treated with four cycles of carboplatin area under the curve (AUC) 5 and doxorubicin (50 mg/m(2)) for four cycles before or after four cycles of carboplatin AUC5 and paclitaxel (175 mg/m(2)) with each cycle administered at 21-day intervals.
  • The overall response rates for patients with evaluable disease were 82.1% and 66.7% for endometrial and carcinosarcoma, respectively.
  • At a median follow-up of 21 months, the median progression-free survival for the endometrial adenocarcinoma and carcinosarcoma cohorts were 15.3 and 12.0 months, respectively.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542250.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


19. Bakrin N, Cotte E, Sayag-Beaujard A, Raudrant D, Isaac S, Mohamed F, Gilly FN, Glehen O: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. Int J Gynecol Cancer; 2010 Jul;20(5):809-14
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity.
  • Our objective was to determine if cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a feasible therapeutic option for treatment of peritoneal recurrence of endometrial carcinoma.
  • Between August 2002 and May 2007, 5 patients with recurrent endometrial carcinoma confined to the peritoneal cavity who underwent CRS with HIPEC.
  • Of the 5 patients treated, histopathological type and International Federation of Gynecology and Obstetrics stage were as follows: IB endometrioid (n = 1), IIIA endometrioid (n = 1), IIIC endometrioid (n = 2), and IC endometrioid + pseudosarcomatoid component (n = 1).
  • One patient with pseudosarcomatoid component developed recurrent disease 10 months after surgery and died 2 months later.
  • Regarding the toxicity of the procedure, highly selected patients with recurrent endometrial carcinoma confined to the peritoneal cavity may benefit from improved survival after CRS with HIPEC.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Peritoneal Neoplasms / therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973274.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Salihoğlu Y, Keskin N, Topuz S, Küçücük S, Iyibozkurt C: Analysis of vaginal recurrences in stage I endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2007;28(4):313-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of vaginal recurrences in stage I endometrial adenocarcinoma.
  • OBJECTIVE: To determine the risk of vaginal recurrence in Stage 1 endometrial cancer and treatment morbidity associated with different therapeutic approaches MATERIAL AND METHODS: Between 1995 and 2005, 341 patients with clinical Stage I endometrial cancer were treated at Istanbul Medical Faculty.
  • Nine patients (6.25%) developed recurrent disease, three of whom had vaginal recurrences.
  • CONCLUSION: This selective treatment protocol for patients with Stage I endometrial cancer avoided radiation entirely in 38% of the patients while achieving a very low rate of vaginal recurrence and good overall survival.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Squamous Cell / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Vagina / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713101.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Wang Q, Hong L, Wang JL, Yue MG, Li HB, Li Y: [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):300-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
  • OBJECTIVE: Both (18)F-fluorodeoxyglucose (FDG) imaging and serum tumor marker measurements can be used in the post-therapy surveillance of recurrent endometrial carcinoma, but the relationship between those two methods has not been demonstrated yet.
  • The purpose of this study was to compare the diagnostic efficiency of (18)F-FDG imaging and serum tumor marker measurements in the diagnosis of recurrent endometrial carcinoma, as well as to analyze the correlation between those two methods.
  • METHODS: Thirty-five patients with histopathologically confirmed endometrial carcinoma and suspected to have recurrent disease during post-therapy surveillance were included in this study. (18)F-FDG images from the thorax to the pelvis were obtained in all patients by using GE-Millennium VG Hawkeye system, and the abnormal FDG uptake was judged as tumor recurrence.
  • Based on the final clinical diagnosis, the efficiency of tumor markers (CA-125, CP-2) and (18)F-FDG imaging in the diagnosis of recurrent tumor was evaluated.
  • CONCLUSION: For the post-therapy surveillance of patients with endometrial carcinoma, serum CA-125 is a high specific tumor marker for diagnosing recurrent disease and better than CP-2, but (18)F-FDG imaging is better than CA-125, and there is a positive correlation between tumor volume and serum CA-125 value.
  • [MeSH-major] CA-125 Antigen / blood. DNA-Binding Proteins / blood. Endometrial Neoplasms / diagnosis. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / diagnosis. Transcription Factors / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Biomarkers, Tumor / blood. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Follow-Up Studies. Humans. Middle Aged. Positron-Emission Tomography. Radiopharmaceuticals. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510085.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DNA-Binding Proteins; 0 / Radiopharmaceuticals; 0 / TFCP2 protein, human; 0 / Transcription Factors; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Akizuki S, Katsumata N, Yamanaka Y, Andoh M, Fujiwara Y, Watanabe T: Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. Int J Clin Oncol; 2005 Aug;10(4):272-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
  • We evaluated the feasibility of weekly paclitaxel in patients with recurrent or advanced endometrial carcinoma who had failed treatment with cyclophosphamide, doxorubicin, and cisplatin (CAP).
  • We treated four patients with CAP-resistant recurrent or advanced endometrial carcinoma with paclitaxel.
  • Outpatient treatment with weekly paclitaxel was well-tolerated and feasible for patients with CAP-resistant recurrent or advanced endometrial carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Endometrioid / drug therapy. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / secondary. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Doxorubicin / therapeutic use. Feasibility Studies. Female. Humans. Infusions, Intravenous. Maximum Tolerated Dose. Middle Aged. Salvage Therapy. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2365-9 [11981009.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):32-4 [9007118.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):235-42 [8098996.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):290-1 [8638543.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3353-61 [9779712.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1021-9 [11181665.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):816-25 [8631019.001]
  • [Cites] Int J Clin Oncol. 2003 Feb;8(1):45-8 [12601542.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Aug;29(8):1371-6 [12214463.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-62-S15-67 [9346225.001]
  • (PMID = 16136374.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; CISCA protocol
  •  go-up   go-down


23. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol; 2007 Mar;18(3):409-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
  • BACKGROUND: Cytotoxic chemotherapy has a limited place in the management of advanced or recurrent endometrial cancer.
  • While early-stage endometrial adenocarcinoma is a common gynaecological cancer with a favourable prognosis, advanced or recurrent disease presents a difficult management problem.
  • Data were extracted from trial reports or supplied by investigators.
  • Future developments are likely to exploit specific molecular characteristics of endometrial cancers, including their hormone dependence, growth factor target overexpression and PTEN loss.
  • While no one drug or regimen offers a clear benefit for women with advanced endometrial cancer, platinum drugs, anthracyclines and paclitaxel seem the most promising agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150999.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861323
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 57
  •  go-up   go-down


24. Nishio S, Koyanagi T, Miyabe K, Kuromatsu H: [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)]. Gan To Kagaku Ryoho; 2010 Apr;37(4):735-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
  • We report two cases of multidrug-resistant endometrial cancer which recurred after the initial therapy and progressed despite further anticancer chemotherapy, but could be successfully treated with medroxyprogesterone acetate (MPA).
  • The first patient with stage IVb moderately-differentiated endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy followed by maintenance chemotherapy.
  • The second patient with stage IIIc poorly-differentiated endometrioid adenocarcinoma of the uterine corpus developed lung metastases 14 months after the initial operation and postoperative chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414038.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


25. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A: Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol; 2008 Sep 10;26(26):4319-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
  • PURPOSE: Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression.
  • PATIENTS AND METHODS: A multinomial design two-stage phase II study was performed to evaluate single-agent activity of erlotinib in women with advanced endometrial cancer with recurrent or metastatic disease who were chemotherapy naïve and had received up to one line of prior hormonal therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use


26. Linkov F, Yurkovetsky Z, Taioli E, Havrilesky LJ, Maxwell GL, Lokshin A: Endometrial cancer: multiplexed Luminex approaches for early detection. Expert Opin Med Diagn; 2008 May;2(5):527-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer: multiplexed Luminex approaches for early detection.
  • BACKGROUND: Endometrial carcinoma is the most common gynecologic cancer.
  • Despite the advances that have been made in other cancers, both the annual incidence of and the death rate associated with endometrial cancer appear to be rising, both in the US and around the world.
  • Adenocarcinoma, which originates in surface cells of the endometrium, accounts for ∼ 90% of cases of endometrial cancer.
  • At this time, there are no early detection tests or exams that can find endometrial cancer early in women without symptoms.
  • OBJECTIVE: There is growing interest in the use of biomarker approaches for the early detection of endometrial cancer.
  • Endometrial cancer has been linked to altered growth factor signaling, immune inflammatory responses and angiogenesis.
  • This article provides an overview of endometrial cancer and outlines the rationale and need for the clinical application of multiplexed ELISA-based assays for the early detection of cancer.
  • Although endometrial cancer has a generally favorable long-term outcome, its screening and diagnosis pose a challenge in women without symptoms.
  • METHOD: An extensive literature review of biomarker approaches to endometrial cancer detection has been performed.
  • CONCLUSION: In the authors' published studies, it was hypothesized that an expanded panel of biomarkers comprised of cytokines, chemokines, growth factors and other tumor markers, which individually may show some promising correlation with disease status, might provide higher diagnostic power if used in combination, especially in the case of endometrial cancer detection.
  • It was also discovered that prolactin may be very important for endometrial cancer detection.
  • In this article, the potential clinical role for using multimarker testing in the early detection of endometrial cancer and for tumor surveillance to permit early identification of recurrence in patients with recurrent disease is discussed.
  • Additionally, the role of lifestyle factors in the endometrial cancer development and prevention is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23495741.001).
  • [ISSN] 1753-0059
  • [Journal-full-title] Expert opinion on medical diagnostics
  • [ISO-abbreviation] Expert Opin Med Diagn
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Mountzios G, Bamias A, Voulgaris Z, Rodolakis A, Vlahos G, Gourgoulis G, Papaiakovou EE, Giannopoulos A: Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model. Gynecol Oncol; 2008 Jan;108(1):130-5
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
  • OBJECTIVE: Taxane-based chemotherapy has been recently introduced as an effective therapeutic option in recurrent or metastatic endometrial carcinoma (RMEC).
  • Non-endometriod histology was associated with a shorter median survival compared to endometriod adenocarcinoma (14.46 vs. 17.57 months, p=0.093), but histology was not an independent prognostic factor (HR=1.43, 95% CI: 0.82-2.48, p=0.21).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988722.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA, Hellenic Co-operative Oncology Group: Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol; 2008 Jul;110(1):87-92
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
  • OBJECTIVE: Taxanes, anthracyclines, and platinum compounds represent the chemotherapeutic agents with the greatest activity in metastatic endometrial carcinoma.
  • We administered the combination of paclitaxel, epirubicin and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity.
  • CONCLUSIONS: The combination of paclitaxel, epirubicin and carboplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Epirubicin / administration & dosage. Female. Greece. Humans. Injections, Intravenous. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Patient Selection. Recurrence

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455782.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Ben-Arie A, Tamir S, Dubnik S, Gemer O, Ben Shushan A, Dgani R, Peer G, Barnett-Griness O, Lavie O: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):813-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer?
  • The objective of the study was to compare the outcome measures of patients with endometrial adenocarcinoma diagnosed by endometrial biopsy, uterine curettage, or hysteroscopy.
  • Medical records of 392 women diagnosed with apparent early-stage endometrial adenocarcinoma were reviewed.
  • During the study period, 99 (25.3%) cases were diagnosed by endometrial biopsy, 193 (49.2%) by uterine curettage, and 100 (25.5%) by hysteroscopy.
  • There were 347 (88.5%) cases of endometrioid adenocarcinoma and 45 (11.5%) of poor histologic types, including serous papillary, clear cell, and small cell cancer.
  • Recurrent disease occurred in 6.9% patients, of which 50% had local recurrence and 50% had distant.
  • Recurrent disease was found in 15.2% patients diagnosed by endometrial biopsy, in 4.7% where uterine curettage was used, and in 5% when hysteroscopy was applied.
  • No statistically significant difference in the survival rate between the different diagnostic methods applied was found, although a higher recurrence rate was noted following endometrial biopsy.
  • After a median follow-up time of 25 months for patients undergoing hysteroscopy, there was no difference in recurrence rates and/or overall survival compared to other diagnostic procedures implying that hysteroscopy can be safely used in the diagnosis of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / surgery. Hysteroscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961159.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


30. Kennedy NA, Dawe S: Atypical paraneoplastic pemphigus secondary to endometrial carcinoma with no mucosal involvement. Clin Exp Dermatol; 2009 Jul;34(5):e130-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical paraneoplastic pemphigus secondary to endometrial carcinoma with no mucosal involvement.
  • We report a case of a 78-year-old woman presenting with an atypical form of PNP associated with a recurrence of endometrial cancer.
  • These ceased after resection of her recurrent endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Endometrial Neoplasms / complications. Paraneoplastic Syndromes / etiology. Pemphigus / etiology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438579.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Fyles A, Wood G, Li M, Manoukian AS, Gowing K, Khokha R, Chapman W, Tsao MS: Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice. Gynecol Oncol; 2008 Feb;108(2):395-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.
  • OBJECTIVE: Hormonal therapy for type I (endometrioid) endometrial carcinoma is employed as both a conservative treatment option and for advanced or recurrent disease, but outcome is often poor.
  • Our objective was to test whether ovariectomy, or ovariectomy followed by progestin treatment prevents the development of endometrial lesions in the pten+/- mouse model of endometrial cancer.
  • RESULTS: Without MPA treatment, 16 of 18 ovariectomized animals developed endometrial neoplasms (atypical hyperplasia or adenocarcinoma), as did all 9 sham surgery mice.
  • All 10 mice treated with either low or high-dose MPA developed endometrial tumors, again with persistent activation of the PI3K signaling pathway.
  • CONCLUSIONS: Development of endometrial neoplasms and constitutive activation of the PI3K pathway in pten+/- mice is not affected by hormonal ablation or by progestin treatment.
  • Loss of PTEN expression is common during human endometrial cancer development, and this may render lesions resistant to the effects of hormonal manipulation leading to treatment failure.
  • [MeSH-major] Endometrial Neoplasms / genetics. Endometrial Neoplasms / prevention & control. Medroxyprogesterone Acetate / pharmacology. PTEN Phosphohydrolase / genetics

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048091.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] C2QI4IOI2G / Medroxyprogesterone Acetate; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


32. Kinugasa Y, Morishige K, Kamiura S, Tsukamoto Y, Saji F: Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma. Jpn J Clin Oncol; 2006 Feb;36(2):113-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma.
  • The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy.
  • The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion.
  • Salvage chemotherapy (paclitaxel and calboplatin) was started from 5 months after surgery when recurrent tumors were detected in the peritoneum and liver.
  • To the best of our knowledge, this is the first reported case of hypercalcemia due to PTHrP secretion in uterine endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / pathology. Hypercalcemia / etiology. Parathyroid Hormone-Related Protein / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418186.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


33. van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ, Lybeert ML, van den Berg HA, Coebergh JW: Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):125-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study.
  • PURPOSE: To compare the health-related quality of life (HRQOL) among 5-10-year survivors of Stage I-II endometrial (adeno-)carcinoma (EC) treated with surgery alone or surgery with external beam adjuvant radiotherapy (EBRT) and an age-matched norm population.
  • The analyses were restricted to women with Stage I-II disease at diagnosis, treated with either surgery alone or surgery with adjuvant EBRT, and without recurrent disease or new primary malignancies (n = 264).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Health Status. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544600.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Semczuk A, Skomra D, Rybojad P, Jeczeń R, Rechberger T: Endometrial carcinoma with pleural metastasis: A case report. Acta Cytol; 2006 Nov-Dec;50(6):697-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma with pleural metastasis: A case report.
  • CASE: An unusual case occurred of recurrent pleural malignant effusion associated with disseminated serous papillary endometrial adenocarcinoma (EC).
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152287.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Sodano M, Bogliatto F, Morero S, Mosso L, Torchio B, Leidi L: Case report: Successful IVF programme after conservatively treated endometrial cancer. Reprod Biomed Online; 2009 Apr;18(4):578-81
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Successful IVF programme after conservatively treated endometrial cancer.
  • Some cases of successful pregnancy after conservative endometrial cancer management have been reported.
  • This paper presents such a case, an infertile patient with conservatively treated endometrial cancer (stage 1a grade 1) who conceived and carried a successful pregnancy after IVF treatment.
  • At the end of the treatment the endometrial cancer remitted to simple endometrial hyperplasia.
  • The histological evaluation after delivery showed no evidence of recurrent disease.
  • It is concluded that conservative treatment of stage 1a and grade 1 endometrial adenocarcinoma is an available option in young women who wish to preserve their fertility.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Embryo Transfer / methods. Endometrial Neoplasms / drug therapy. Fertilization in Vitro / methods. Megestrol Acetate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401002.001).
  • [ISSN] 1472-6491
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


36. Uharcek P, Mlyncek M, Ravinger J, Matejka M: Prognostic factors in women 45 years of age or younger with endometrial cancer. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):324-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in women 45 years of age or younger with endometrial cancer.
  • The purpose of this study was to conduct a clinical and pathologic review of endometrial cancers diagnosed in women aged younger than 45 years to better identify the prognostic factors for this subgroup of women.
  • We retrospectively evaluated the clinical history, treatment, and follow-up of patients with histologically confirmed endometrial cancer treated in Faculty Hospital Nitra, Slovakia from 1993 to 2003.
  • One hundred seventy-three patients with endometrioid histology were divided into two groups: younger group (age <or=45 years, n = 20) and older group (age >45, n = 153).
  • Twenty patients less than or equal to 45 years of age received treatment for endometrial cancer: stage I, 16 (80%); stage II, 2 (10%); stage III, 1 (5%); and stage IV, 1 (5%).
  • At the end of study period, 17 (85%) were alive with no evidence of disease and 3 (15%) had died of recurrent disease.
  • Majority of young patients with endometrial cancer were obese and nulliparous.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334010.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Misawa A, Nagao M, Kushimoto T, Yasuda M: [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1901-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
  • Standard chemotherapy for endometrial cancer, including therapy with adriamycin and cisplatin (AP therapy), has not been established.
  • We retrospectively investigated 46 patients with endometrial cancer who were diagnosed and treated in our hospital.
  • As a rule, 6 courses of TC therapy (paclitaxel (PTX): 180 mg/m2, carboplatin (CBDCA): AUC 5), as initial chemotherapy, were performed at 3-week intervals in 18 patients with advanced or recurrent cancer from whom informed consent was obtained.
  • In endometrioid adenocarcinoma patients, the response rate was 66.6%.
  • Two patients with a partial response (PR) (1 with endometrioid adenocarcinoma, 1 with serous adenocarcinoma) achieved a disease-free survival of more than 30 months.
  • Thus, TC therapy may be effective for endometrial cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Endometrial Neoplasms / drug therapy. Paclitaxel / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011339.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


38. Dvalishvili I, Charkviani L, Turashvili G, Burkadze G: Clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grade. Georgian Med News; 2006 Mar;(132):24-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grade.
  • The aim of this study was to compare clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grades.
  • We have studied 104 postmenopausal women with a histological diagnosis of uterine endometrioid adenocarcinoma.
  • Histological examination has showed grade 1 endometrioid adenocarcinoma in 35 cases (33,7%, group 1), grade 2 adenocarcinoma in 44 cases (42,3%, group 2), and grade 3 adenocarcinoma in 25 cases (24%, group 3).
  • Most of the factors we have examined seem to be associated with histological grade of uterine endometrioid carcinoma.
  • The analysis of clinicopathological prognostic factors in G1 endometrioid adenocarcinoma cases has showed that about half of these patients are obese, vaginal bleeding is not common, no cervical involvement, parametrium invasion, adnexal metastasis and vessel permeation at the time of diagnosis, no recurrence within two years, pre-surgery value of CA125 is normal, and myometrial invasion is less than 1/3.
  • G3 endometrioid adenocarcinoma cases have showed family history of endometrial cancer, more than half of the patients were obese, with uncommon vaginal bleeding and positive peritoneal cytology, but cervical involvement, parametrium invasion, adnexal metastasis and vessel permeation are present at the time of diagnosis, pre-surgery value of CA125 is high, and myometrial invasion is 2/3 or more than 2/3 in majority of cases, furthermore, in some cases recurrent tumors were developed within two years.
  • G2 endometrioid adenocarcinoma can be considered as an intermediary form which should be managed according to the clinical stage.
  • The results lead to conclude that the histological grade of uterine endometrioid adeno carcinoma seems to be an important independent prognostic indicetor as it is strongly associated with other clinical pathological prognostic factors.
  • [MeSH-major] Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636372.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


39. Pellerin GP, Finan MA: Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol; 2005 Nov;193(5):1640-4
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis.
  • OBJECTIVE: The purpose of this study was to evaluate the experience with endometrial carcinoma in women < or =45 years of age at Ochsner Clinic Foundation, New Orleans, La.
  • STUDY DESIGN: We evaluated the clinical history, treatment, and follow-up of 38 women < or =45 years of age diagnosed with endometrial cancer.
  • RESULTS: Thirty-eight patients received primary treatment for endometrial cancer: stage I, 32 (84.2%); stage II, 1 (2.6%); stage III, 4 (10.5%); stage IV, 1 (2.6%).
  • At end of study period 32 women (84.2%) were alive with no evidence of disease, 5 had died of recurrent disease, and 1 died of metastatic breast cancer.
  • [MeSH-major] Adenocarcinoma. Endometrial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260203.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Temkin SM, Hellman M, Lee YC, Abulafia O: Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases. J Low Genit Tract Dis; 2007 Apr;11(2):118-21
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases.
  • OBJECTIVE: Endometrial cancer generally carries a good prognosis.
  • However, 10% to 15% of patients will manifest recurrent disease.
  • CASE 1: A 63-year-old patient presented 7 years after treatment of endometrial cancer with a vulvar lesion and groin mass.
  • The lesions were successfully resected and confirmed to be recurrent endometrial cancer.
  • CASE 2: An 83-year-old patient with a history of a hysterectomy for endometrial cancer and radiation therapy for a vaginal vault recurrence presented with an exophytic labial mass.
  • After radical wide excision of her vulvar mass and bilateral groin dissection, final pathology revealed that the mass was consistent with recurrent endometrial cancer.
  • CONCLUSIONS: Uncommon sites of recurrence of endometrial cancer may include the vulva.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / pathology. Gynecologic Surgical Procedures. Vulvar Neoplasms / surgery

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415118.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, Shozu M, Isaka K: Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod; 2007 Jul;22(7):1953-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer.
  • BACKGROUND: There are therapeutic dilemmas regarding conservative management of endometrial cancer in young women.
  • METHODS: We planned a prospective study to conservatively treat women aged under 40 years with clinical stage 1A, grade 1 endometrioid adenocarcinoma from 1999 to 2005.
  • Two patients developed recurrent disease 10 and 22 months after the last dilatation and curettage, and both had synchronous ovarian cancer.
  • CONCLUSIONS: Patients with an initial PR can obtain CR after further treatment, and the PgR may be useful in predicting CR to fertility-preserving treatment in young women with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Progestins / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449880.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Progestins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


42. Moxley KM, McMeekin DS: Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist; 2010;15(10):1026-33
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.
  • Adenocarcinoma of the endometrium represents the most common gynecologic malignancy in developed countries.
  • Chemotherapy has evolved into an important modality in high-risk early-stage and advanced-stage disease, and in recurrent endometrial cancer.
  • Taxane-based therapy consistently demonstrates the highest response rates in the first-line and salvage settings of endometrial cancer.
  • Chemotherapy resistance mediated by overexpression of drug efflux pump proteins and mutations in β-tubulin isoforms in both primary and recurrent disease represent unique treatment challenges and highlight the need for new agents that are less susceptible to these known resistance pathways.
  • Epothilone B analogs are novel cytotoxic agents with activity in solid tumors, including advanced/recurrent endometrial carcinoma, and may have unique properties that can overcome resistance in some settings.
  • These agents alone and in combination represent a new therapeutic opportunity in endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Mar;14(3):441-8 [12598351.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):179-86 [11469885.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1173-8 [15277255.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1317-25 [1442985.001]
  • [Cites] Eur J Cancer. 1993;29A(4):554-8 [8094623.001]
  • [Cites] Cell Struct Funct. 1993 Jun;18(3):173-82 [7902216.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Int J Cancer. 1995 Dec 11;63(6):798-803 [8847137.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):17118-25 [9202030.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1282-93 [9276747.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1377-82 [10523715.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1635-8 [15523093.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2774-9 [16675570.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):266-71 [16868539.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):155-9 [16545437.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):16-22 [17574073.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2983-90 [17617530.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):226-33 [17996926.001]
  • [Cites] Apoptosis. 2008 Feb;13(2):259-71 [18071906.001]
  • [Cites] Obstet Gynecol. 2008 Feb;111(2 Pt 1):436-47 [18238985.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):207-12 [18317222.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii19-20 [18456753.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66 [18347795.001]
  • [Cites] Clin Ther. 2008 Sep;30(9):1590-617 [18840366.001]
  • [Cites] Gynecol Oncol. 2008 Oct;111(1):22-6 [18675446.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10197-204 [19074887.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8123-31 [19088027.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1207-23 [19088324.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):17-25 [19139109.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):543-52 [19108877.001]
  • [Cites] Int J Gynaecol Obstet. 2009 May;105(2):103-4 [19367689.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):13023-32 [19282281.001]
  • [Cites] Endocr Relat Cancer. 2009 Jun;16(2):363-80 [19190080.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3104-8 [19451430.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5331-6 [19805679.001]
  • [Cites] Eur J Gynaecol Oncol. 2009;30(5):514-7 [19899405.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):149-53 [19917861.001]
  • [Cites] Mol Cancer Ther. 2009 May;8(5):1055-66 [19435871.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1786-93 [10561216.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):O1-9 [11342188.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • (PMID = 20930101.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3227900
  •  go-up   go-down


43. Amato NA, Partipilo V, Mele F, Boscia F, De Marzo P: [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)]. Minerva Ginecol; 2009 Feb;61(1):1-12
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
  • [Transliterated title] Linfoadenectomia pelvica come alternativa alla radioterapia adiuvante nel carcinoma endometriale ad alto rischio di metastasi linfonodali in fase precoce (stadio I).
  • AIM: The aim of this study was to evaluate if the surgical approach without pelvic lymphadenectomy and with adjuvant radiotherapy in the patients suffering from endometrioid adenocarcinoma type at high risk (of lymphatic metastasis) in early stage can be substituted by only surgery with pelvic lymphadenectomy (with or without para-aortic lymphadenectomy).
  • The cancer grading (G) was defined before the surgery with an hystological exam on endometrial biopsies.
  • [MeSH-major] Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Lymph Node Excision. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19204656.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


44. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer; 2009 Aug;19(6):1068-73
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
  • INTRODUCTION: The purpose of this study was to evaluate the efficacy of conservative treatment with progestin and pregnancy outcomes in women with early-stage endometrial cancer.
  • METHODS: We retrospectively analyzed the medical records of 35 patients with endometrial adenocarcinoma, who were treated with progestin from January 1996 to December 2006.
  • Women with early-stage grade 1 endometrioid endometrial adenocarcinoma, who wanted to receive conservative treatment or preserve fertility, were included.
  • Complete remission (CR) was defined as no evidence of endometrial adenocarcinoma or hyperplasia.
  • Partial remission was diagnosed when the patient developed endometrial hyperplasia, and persistent disease was defined as residual endometrial adenocarcinoma by pathologic confirmation.
  • Of the 22 patients with CR, 9 (40.9%) had recurrent disease, and the median time to recurrence was 12 months (range, 8-48 months).
  • CONCLUSIONS: Conservative treatment with progestin can be considered a good therapeutic option in patients with well-differentiated early-stage endometrioid endometrial adenocarcinoma who wish to preserve their uteri or become pregnant.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / rehabilitation. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / rehabilitation. Pregnancy Outcome. Progestins / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820370.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


45. Lim MC, Lee SM, Lee J, Choi HJ, Lee S, Huh CY, Park SY: Endometrioid adenocarcinoma in urethrovaginal septum: a diagnostic pitfall. J Korean Med Sci; 2009 Feb;24(1):162-5
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma in urethrovaginal septum: a diagnostic pitfall.
  • Primary endometrioid adenocarcinoma developed at urethrovaginal septum has not been reported.
  • A 61-yr-old woman presented with recurrent urinary tract infection.
  • A pinpoint ulceration at slightly elevated anterior vaginal wall was found and biopsy revealed endometrioid adenocarcinoma.
  • Microscopic finding of the pathology revealed endometrioid adenocarcinoma.
  • This is the first reported case of extraovarian endometrioid adenocarcinoma developed at the urethrovaginal septum.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Urethral Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1970 Aug;36(2):251-6 [5428492.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):58-63 [6420243.001]
  • [Cites] Hinyokika Kiyo. 1988 Apr;34(4):696-700 [3041781.001]
  • [Cites] Obstet Gynecol. 2006 Sep;108(3 Pt 2):753-5 [17018491.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(1):39-41 [9476057.001]
  • [Cites] Jpn J Clin Oncol. 2005 Mar;35(3):154-7 [15741306.001]
  • [Cites] Gynecol Oncol. 1989 Aug;34(2):232-6 [2666285.001]
  • (PMID = 19270832.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2650998
  • [Keywords] NOTNLM ; Carcinoma, Endometrioid / Urethrovaginal Septum
  •  go-up   go-down


46. Maxwell GL, Tian C, Risinger JI, Hamilton CA, Barakat RR, Gynecologic Oncology Group Study: Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy? Cancer; 2008 Sep 15;113(6):1431-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?
  • BACKGROUND: Population-based studies suggest that, because of inequalities in treatment, black women with localized endometrial cancer have shorter survival compared with white women.
  • The objective of the current investigation was to determine whether there is a racial disparity in outcome between black patients and white patients with early-stage endometrial cancer treated similarly in a clinical trial setting.
  • METHODS: A retrospective review of 110 black patients and 1,049 white patients with stage I and II endometrial cancer (graded according to the International Federation of Gynecology and Obstetrics grading system) was performed using data from a randomized, placebo-controlled trial performed by the Gynecologic Oncology Group that evaluated postoperative estrogen replacement therapy (ERT) and the risk of cancer recurrence.
  • Within a median follow-up of 3 years, 5 of 56 black patients with endometrial cancer in the ERT group were identified with recurrent disease compared with only 8 of 521 white patients.
  • CONCLUSIONS: The findings of the current study suggested that recurrence-free survival may be shorter among black women with stage I endometrial cancer, even in a clinical trials setting in which patients receive similar treatment and follow-up.
  • This increased risk of recurrence appeared to be most evident in black women with endometrial cancer who maintained ERT after primary treatment.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698590.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA027469-28; United States / NCI NIH HHS / CA / U10 CA037517-24; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS58648; NLM/ PMC4435958
  •  go-up   go-down


47. Brown AK, Gillis S, Deuel C, Angel C, Glantz C, Dubeshter B: Abnormal cervical cytology: a risk factor for endometrial cancer recurrence. Int J Gynecol Cancer; 2005 May-Jun;15(3):517-22
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal cervical cytology: a risk factor for endometrial cancer recurrence.
  • The objective of this study was to evaluate the relationship between cervical cytology, histologic type, and risk of endometrial cancer recurrence.
  • We performed a retrospective study of patients undergoing surgery for endometrial carcinoma.
  • Abnormal cervical cytology was defined as the presence of any endometrial cells on Pap smear.
  • Thirty-nine (9%) patients developed recurrent endometrial cancer.
  • For endometrioid adenocarcinoma, abnormal cervical cytology occurred in 61% and 7% recurred, while with high-risk histologies, 84% had abnormal cervical cytology and 19% recurred (P < 0.05).
  • Abnormal cervical cytology is associated with increased risk of endometrial cancer recurrence.
  • [MeSH-major] Carcinoma / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local. Papanicolaou Test. Vaginal Smears


48. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, Gold MA, McMeekin DS, Modesitt S, Cooper AL, Powell MA, Mutch DG, Nag S, Alvarez RD, Cohn DE: Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):886-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.
  • The objective of this study was to evaluate the treatment outcomes and risk factors of women with surgical stage I endometrial adenocarcinoma who were initially treated with surgery alone and subsequently developed isolated vaginal recurrences.
  • Patients with surgical stage I endometrial adenocarcinoma diagnosed from 1975 to 2002 were identified from tumor registry databases at seven institutions.
  • Sixty-nine women with surgical stage I endometrial cancer with isolated vaginal recurrences were identified.
  • Among women, 18% died from subsequent recurrent disease.
  • The majority of isolated vaginal recurrences in women with surgical stage I endometrial cancer can be successfully salvaged with radiation therapy, further questioning the role of adjuvant therapy for patients with uterine-confined endometrial cancer at the time of initial diagnosis.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309665.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


49. Grendys EC Jr, Blessing JA, Burger R, Hoffman J: A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol; 2005 Aug;98(2):249-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
  • OBJECTIVE: A phase II study was conducted to determine the efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments.
  • METHODS: Eligible patients with measurable disease who failed primary therapy including one cytotoxic regimen were eligible for the trial.
  • CONCLUSION: Flavopiridol as a single agent in the above dosing schedule appears to have minimal activity as second-line chemotherapy of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Flavonoids / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Piperidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978659.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Piperidines; 45AD6X575G / alvocidib
  •  go-up   go-down


50. Morrison C, Miecznikowski J, Darcy KM, Dolce JM, Kandel E, Erwin DO, Liu S, Shepherd L, Cohn D, McMeekin DS, Block AW, Nowak NJ, Maxwell L: A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome. Genes Chromosomes Cancer; 2010 Sep;49(9):791-802
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome.
  • The goal of this study was to identify recurrent regions of genomic gain or loss in endometrial cancer of the endometrioid type in the context of racial disparities in mortality for this disease.
  • A separate subset of 220 endometrial cancers with outcome data was used for validation.
  • When subdivided into various groups of risk by stage and grade the survival curves showed a decreased survival for high grade and/or stage tumors, but not for low grade and/or stage endometrioid tumors.
  • [MeSH-major] African Americans / genetics. Comparative Genomic Hybridization. Endometrial Neoplasms / ethnology. Endometrial Neoplasms / genetics. European Continental Ancestry Group / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / ethnology. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / ethnology. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / therapy. Chromosomes, Human, Pair 1 / genetics. Cystadenocarcinoma, Serous / ethnology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / therapy. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20607851.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol; 2008 Aug;110(2):196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease.
  • The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.
  • METHODS: Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125.
  • RESULTS: Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed.
  • CONCLUSION: HE4 is elevated in all stages of endometrial can100cer and is more sensitive in early-stage endometrial cancer compared to CA125.
  • Further investigation of HE4 as a marker for early detection of recurrent endometrial cancer and monitoring response to therapy is warranted.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Epididymal Secretory Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):201-9 [12713981.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1195-7 [12748476.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):292-7 [8088605.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):321-6 [8088608.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1316-9 [8623863.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):967-70 [9038731.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):291-6 [9159340.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):397-400 [10468891.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):315-7 [10475131.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • (PMID = 18495222.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS243878; NLM/ PMC3594093
  •  go-up   go-down


52. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer; 2010 Jan 5;102(1):134-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
  • BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a rare but highly aggressive variant of endometrial cancer.
  • Pertuzumab significantly increases tratuzumab-induced ADCC against USPC with a low HER2/neu expression and may represent a new therapeutic agent in patients harbouring advanced/recurrent and/or refractory USPC.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857841 for PMID:19920829 [PharmGKB] .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. Pertuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Aug;102(2):128-31 [18555254.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):47-86 [11385776.001]
  • [Cites] Eur J Immunol. 2001 Oct;31(10):3016-25 [11592078.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1271-9 [12006548.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):127-37 [12204533.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2440-6 [12855616.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2343-6 [15059883.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2601-9 [15059917.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3126-32 [15284264.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5650-5 [15355889.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):4087-91 [1972347.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • [Cites] Int J Cancer. 1996 Mar 1;65(5):688-94 [8598323.001]
  • [Cites] J Virol. 1999 Jul;73(7):5402-10 [10364287.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2534-43 [15699478.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):24-30 [15894362.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1391-7 [16116605.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2701-8 [16265675.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):139-44 [16182348.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):259-67 [16404427.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jun;55(6):717-27 [16151804.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4324-32 [16896006.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902 [17009989.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):93-100 [17237269.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11991-9 [18089830.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):3-9 [17945336.001]
  • [Cites] Obstet Gynecol. 2008 Feb;111(2 Pt 1):436-47 [18238985.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • (PMID = 19920829.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016359; United States / NCI NIH HHS / CA / R01 CA122728; United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / R01 CA122728-01A2
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Interleukin-2; 380610-27-5 / pertuzumab; 9007-36-7 / Complement System Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2813756
  •  go-up   go-down


53. Ghezzi F, Cromi A, Bergamini V, Uccella S, Beretta P, Franchi M, Bolis P: Laparoscopic-assisted vaginal hysterectomy versus total laparoscopic hysterectomy for the management of endometrial cancer: a randomized clinical trial. J Minim Invasive Gynecol; 2006 Mar-Apr;13(2):114-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted vaginal hysterectomy versus total laparoscopic hysterectomy for the management of endometrial cancer: a randomized clinical trial.
  • STUDY OBJECTIVE: To compare laparoscopic-assisted vaginal hysterectomy (LAVH) and total laparoscopic hysterectomy (TLH) for the treatment of endometrial cancer.
  • DESIGN: Randomized, controlled trial.
  • DESIGN CLASSIFICATION: Randomized controlled trial (Canadian Task Force classification I).
  • PATIENTS: Seventy-two women with endometrial cancer randomized to undergo either LAVH or TLH.
  • Within a median follow-up period of 10 months (range 3-17 months), 2 patients in the LAVH group developed recurrent disease.
  • CONCLUSION: Both LAVH and TLH can be performed successfully to manage endometrial cancer, with similar surgical outcomes.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Hysterectomy, Vaginal / methods. Hysteroscopy / methods. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Aged. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Laparoscopes. Lymph Node Excision / methods. Middle Aged. Neoplasm Staging. Pain, Postoperative / diagnosis. Pain, Postoperative / epidemiology. Probability. Risk Assessment. Statistics, Nonparametric. Survival Rate

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527713.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


54. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • A 39-yr-old, acyclic, uniparous, female white rhinoceros with a history of recurrent vaginal bleeding was euthanized following a period of respiratory distress and ill-thrift.
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, Niikura H, Okamura K, Yaegashi N, Sasano H, Inoue S: 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer. Clin Cancer Res; 2005 Oct 15;11(20):7384-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
  • PURPOSE: We examined expression of 14-3-3sigma, a regulator of cell proliferation, and evaluated its clinical significance in endometrioid endometrial carcinoma.
  • EXPERIMENTAL DESIGN: One hundred three endometrioid endometrial adenocarcinoma cases were examined using immunohistochemistry with archival specimens.
  • Patients whose tumors were negative for 14-3-3sigma were at much greater risk to develop recurrent and/or mortal disease (P = 0.0372 and 0.0067).
  • CONCLUSIONS: Results of our study showed that loss or absence of 14-3-3sigma determined by immunohistochemistry may be an important tool to identify endometrial carcinoma cases at high risk of recurrence and/or death, who are otherwise not detected by current clinical and pathologic evaluation, especially in the early stages of the disease.
  • In addition, results of 14-3-3sigma immunohistochemistry in the early stage of endometrial carcinoma could contribute to planning postoperative follow-up and adjuvant therapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / pathology. Exonucleases / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] 14-3-3 Proteins. Disease-Free Survival. Endometrium / chemistry. Endometrium / pathology. Estrogen Receptor alpha / analysis. Exoribonucleases. Female. Humans. Immunohistochemistry / statistics & numerical data. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Receptors, Progesterone / analysis. Survival Analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243811.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


56. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • The median survival for recurrent endometrial cancer was 5 years.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Katsumata N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, Aoki D, Susumu N, Kuramoto H, Jobo T, Ueki K, Ueki M, Kohno I, Fujiwara K, Sohda Y, Eguchi F: Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer; 2005 Oct 31;93(9):999-1004
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
  • The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma.
  • Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status </=2 entered the study.
  • Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Phytogenic / therapeutic use. Endometrial Neoplasms / drug therapy. Salvage Therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / secondary. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Female. Humans. Japan. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1991 Jun;9(6):1071-88 [2033421.001]
  • [Cites] Am J Clin Oncol. 1991 Feb;14(1):36-7 [1987736.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):52-7 [10873410.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2360-4 [11981008.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):78-85 [12504662.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):14-8 [14758127.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Gynecol Oncol. 1980 Aug;10(1):51-4 [7190531.001]
  • [Cites] Cancer Treat Rep. 1982 Aug;66(8):1669-71 [7105059.001]
  • [Cites] Cancer Treat Rep. 1983 Jul-Aug;67(7-8):737-8 [6871892.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1453-5 [8111713.001]
  • [Cites] Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8 [7670132.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):101-4 [8898177.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):610-5 [15721401.001]
  • [Cites] Am J Clin Oncol. 1984 Jun;7(3):253-6 [6539565.001]
  • [Cites] Am J Clin Oncol. 1986 Feb;9(1):15-7 [3953488.001]
  • [Cites] Am J Clin Oncol. 1986 Feb;9(1):21-3 [3754086.001]
  • [Cites] Am J Clin Oncol. 1988 Dec;11(6):612-3 [3055931.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):39-41 [2407103.001]
  • [Cites] Am J Clin Oncol. 1993 Dec;16(6):492-3 [8256763.001]
  • (PMID = 16234823.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Other-IDs] NLM/ PMC2361676
  •  go-up   go-down


58. Park JC, Cho CH, Rhee JH: A successful live birth through in vitro fertilization program after conservative treatment of FIGO grade I endometrial cancer. J Korean Med Sci; 2006 Jun;21(3):567-71
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live birth through in vitro fertilization program after conservative treatment of FIGO grade I endometrial cancer.
  • Infertile women with chronic anovulation are prone to be exposed to unopposed estrogen stimulation and have the high risk of being suffering from endometrial hyperplasia or even endometrial carcinoma.
  • A few reports have suggested that nulliparous young women (under 40 yr of age) with endometrial carcinoma could be treated conservatively to preserve fertility and succeed the live birth.
  • We report on a 36-yr-old woman who received conservative treatment of endometrial carcinoma (stage I, grade 1) by curettage and progestin.
  • After megestrol medication of total 71,680 mg during 24 weeks, we found the regression of endometrial lesion by curettage and hysteroscopic examination.
  • Two years after delivery, she is healthy without any evidence of recurrent disease.
  • The fertility preserving treatment is an option in endometrial cancer patients if carefully selected, and assisted reproductive technologies would be helpful.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Fertilization in Vitro / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):119-22 [10843466.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):434-40 [9277658.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Nov;126(11):619-23 [11079725.001]
  • [Cites] Fertil Steril. 2001 Oct;76(4):826-9 [11591422.001]
  • [Cites] Fertil Steril. 2002 Jan;77(1):188-9 [11779615.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1982 Feb;22(1):38-42 [6954943.001]
  • [Cites] Pathol Res Pract. 1982 Aug;174(3):297-318 [7145772.001]
  • [Cites] Br Med J (Clin Res Ed). 1985 Dec 14;291(6510):1693-7 [3935248.001]
  • [Cites] Obstet Gynecol. 1986 Dec;68(6):741-5 [3785784.001]
  • [Cites] Am J Epidemiol. 1987 May;125(5):780-90 [3565353.001]
  • [Cites] Obstet Gynecol. 1988 Apr;71(4):612-4 [3353053.001]
  • [Cites] Obstet Gynecol. 1995 Jul;86(1):38-42 [7784020.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):255-7 [7622115.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):320-7 [9010105.001]
  • [Cites] Hum Reprod Update. 1996 Jan-Feb;2(1):63-75 [9079404.001]
  • [Cites] Hum Reprod. 1997 May;12(5):959-62 [9194647.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):129-32 [11006045.001]
  • (PMID = 16778408.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Progestins
  • [Other-IDs] NLM/ PMC2729970
  •  go-up   go-down


59. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


60. Kim YM, Lee SW, Kim DY, Kim JH, Nam JH, Kim YT: The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother; 2010 Jun;22(3):197-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
  • This study evaluated the efficacy and toxicity of belotecan (CKD-602), a new camptothecin analogue topoisomerase i inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
  • As a single chemotherapy agent, belotecan was effective in treating recurrent or refractory epithelial ovarian cancer, and had acceptable toxicity.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566426.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 27Z82M2G1N / belotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


61. Cantu de Leon D, Perez Montiel D, Tabarez A, Martinez RM, Cetina L: Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors. World J Surg Oncol; 2009;7:20
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors.
  • CASE PRESENTATION: We report a synchronic fallopian tube adenocarcinoma and a verrucous cervical cancer.
  • A 85-year-old woman with postmenopausal genital hemorrhage, endometrial biopsy was reported as squamous metaplasia, an exploratory laparotomy was performed finding a tubal tumor diagnosed as adenocarcinoma, a staging procedure was performed.
  • The patient has remained in follow-up, and at 9 months, there has been no documented evidence of recurrent disease.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJOG. 2007 Apr;114(4):425-9 [17309544.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(6):501-2 [18179146.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):29-35 [16445606.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2000 Oct;63(10):765-9 [11076434.001]
  • [Cites] Pathol Res Pract. 1998;194(10):713-20 [9820868.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Ugeskr Laeger. 1993 Feb 22;155(8):565-6 [8451794.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1984 Apr;36(4):617-22 [6715942.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1050-4 [14674078.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(1):73-5 [12691323.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Jun;26(3):189-92 [10932980.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Arch Gynecol Obstet. 2008 Jun;277(6):557-62 [18066567.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6C):4491-4 [18214065.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • (PMID = 19222847.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2649116
  •  go-up   go-down


62. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • In the setting of recurrent disease or in women with residual disease after surgery, a platinum-based regimen or enrollment in a clinical trial is recommended.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


63. Benedetti Panici P, De Vivo A, Bellati F, Manci N, Perniola G, Basile S, Muzii L, Angioli R: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol; 2007 Mar;14(3):1136-42
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
  • The aim of this prospective observational trial was to analyze the role of SCR in patients with platinum-sensitive ovarian cancer.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Middle Aged. Observation. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195909.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 49DFR088MY / Platinum
  •  go-up   go-down


64. Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E: Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology; 2007;73(3-4):177-84
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Aged. Aged, 80 and over. Cohort Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Dose-Response Relationship, Drug. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / prevention & control. Humans. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418010.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


65. Seetharamu N, Kim E, Hochster H, Martin F, Muggia F: Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res; 2010 Feb;30(2):541-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the response rates and safety of SPI-77, in patients with recurrent epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Papillary / drug therapy. Cisplatin / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332467.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA009454-21
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / SPI-77, liposomal; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


66. Chase DM, Crade M, Basu T, Saffari B, Berman ML: Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound. Int J Gynecol Cancer; 2009 Apr;19(3):354-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients had recurrent cancer; however, only 1 had a suspicious ultrasound finding.
  • Excluding the recurrent cancers and the observed patients, the positive predictive value (PPV) and the negative predictive value (NPV) of 3D vascular ultrasound were 100% and 95%, respectively.
  • [MeSH-major] Adenocarcinoma, Clear Cell / ultrasonography. Carcinoma, Papillary / ultrasonography. Cystadenocarcinoma, Serous / ultrasonography. Endometrial Neoplasms / ultrasonography. Ovarian Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407559.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Shi H, Pan L, Song T: Impact of platinum on the whole mitochondrial genome of ovarian carcinomas both in vivo and in vitro. Int J Gynecol Cancer; 2009 Apr;19(3):423-30
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate somatic mitochondrial DNA mutation in primary and recurrent ovarian carcinoma tissues as well as that in drug-resistant cell lines to illuminate the impact of chemotherapeutic drugs on mitochondrial DNA (mtDNA).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adult. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / secondary. Drug Resistance, Neoplasm / drug effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Middle Aged. Mutation / genetics. Polymerase Chain Reaction. Polymorphism, Genetic / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407571.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Organoplatinum Compounds
  •  go-up   go-down


68. Gadducci A, Fuso L, Cosio S, Landoni F, Maggino T, Perotto S, Sartori E, Testa A, Galletto L, Zola P: Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer; 2009 Apr;19(3):367-74
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this retrospective investigation was to assess the pattern of failures of 412 patients with recurrent ovarian cancer followed up with different surveillance protocols.Time to recurrence was less than 6 months in 98 women (23.8%), 6 to 12 months in 102 women (24.7%), and more than 12 months in 212 women (51.5%).
  • Among the 331 asymptomatic patients, the surveillance procedure that raised the suspect of recurrent disease was clinical examination in 49 (14.8%), imaging technique in 90 (27.2%), serum CA 125 in 77 (23.3%), and both serum CA 125 and imaging technique in 115 (34.7%).
  • In conclusion, there was no survival difference between asymptomatic and symptomatic patients at the time of relapse, and therefore, the diagnostic anticipation allowed by a scheduled follow-up protocol did not seem to improve the clinical outcome of patients who ultimately developed recurrent disease.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / secondary. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Diagnostic Imaging. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Population Surveillance. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407561.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


69. Marshburn PB, Zhang J, Bahrani-Mostafavi Z, Matthews ML, White J, Hurst BS: Variant progesterone receptor mRNAs are co-expressed with the wild-type progesterone receptor mRNA in human endometrium during all phases of the menstrual cycle. Mol Hum Reprod; 2005 Nov;11(11):809-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant progesterone receptor mRNAs are co-expressed with the wild-type progesterone receptor mRNA in human endometrium during all phases of the menstrual cycle.
  • Progesterone receptor (PR) variant mRNAs in human endometrium could encode proteins with the potential to alter progesterone action in states of normal and abnormal endometrial development.
  • We have assessed the expression levels of mRNA for the wild-type PR and splice variants of PR mRNA lacking exon 4 (del-4 PR), exon 6 (del-6 PR), exons 4 and 6 (del-4&6 PR), and part of exon 4 (del-p4 PR) or part of exon 6 (del-p6 PR) in the human endometrium throughout menstrual cycle development.
  • Eighty-eight endometrial specimens (47 proliferative, 41 secretory) were collected from patients undergoing hysterectomy for benign gynaecologic causes.
  • Measurements by RT-PCR indicated that mRNAs for wild-type PR, and splice variants del-4 PR, del-6 PR, del-4&6 PR, del-p6 PR, and a novel del-p4 PR were detected in all endometrial specimens throughout the menstrual cycle.
  • Higher levels of wild-type PR and all PR variant mRNAs were found in the early and mid-proliferative endometrial phases than in secretory endometrium.
  • The relative expression of mRNA for all PR variants compared to wild-type PR mRNA, however, did not change through all stages of endometrial development.
  • Future studies will determine if the expression profile of PR variant mRNAs will be different in the endometrium of patients with infertility, recurrent pregnancy loss, or endometrial adenocarcinoma.
  • [MeSH-major] Endometrium / physiology. Gene Expression Regulation. Genetic Variation. Menstrual Cycle / physiology. RNA, Messenger / genetics. Receptors, Progesterone / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339776.001).
  • [ISSN] 1360-9947
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, Progesterone
  •  go-up   go-down


70. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M: Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer; 2006 May-Jun;16(3):986-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Aged. Antineoplastic Combined Chemotherapy Protocols. Area Under Curve. CA-125 Antigen / analysis. Carboplatin / therapeutic use. Carcinoma / diagnosis. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Disease-Free Survival. Endometrial Neoplasms / diagnosis. Female. Humans. Necrosis. Ovariectomy / statistics & numerical data. Paclitaxel / therapeutic use. Prognosis. Retrospective Studies. Second-Look Surgery / methods. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803473.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


71. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J: A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet; 2010;11:20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occurrence of the same PALB2 alteration in seven unrelated women suggests that c.509_510delGA (p.R170fs) is a recurrent mutation for Polish population.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Case-Control Studies. Chromatography, High Pressure Liquid. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / secondary. DNA / blood. DNA / genetics. Endometrial Neoplasms / genetics. Endometrial Neoplasms / secondary. Female. Genetic Predisposition to Disease. Haplotypes. Humans. Immunoenzyme Techniques. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Risk Factors. Young Adult


72. Khademi S, Westphalen AC, Webb EM, Joe BN, Badiee S, Hawkins RA, Coakley FV: Frequency and etiology of solitary hot spots in the pelvis at whole-body positron emission tomography/computed tomography imaging. Clin Imaging; 2009 Jan-Feb;33(1):44-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the seven women, increased FDG uptake was due to physiological endometrial uptake (n=2), leiomyoma (n=1), corpus luteum cyst (n=1), physiological ovarian uptake (n=1), urinary leak (n=1), and nonspecific colitis (n=1).
  • In the man, uptake was due to recurrent rectosigmoid adenocarcinoma.
  • CONCLUSION: Isolated pelvic hot spots at PET/CT imaging in an oncological population are not common and usually benign; physiological endometrial or ovarian uptake is the single commonest cause.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2002 Oct;43(10):1339-42 [12368372.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):266-71 [14960646.001]
  • [Cites] J Comput Assist Tomogr. 2004 May-Jun;28(3):340-2 [15100537.001]
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1143-7 [15385321.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):591-603 [10210218.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10):1706-15 [10520713.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Nucl Med Commun. 2005 Aug;26(8):671-87 [16000985.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):757-63 [15772859.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):308-19 [16423932.001]
  • [Cites] Obstet Gynecol Clin North Am. 2006 Mar;33(1):85-95 [16504808.001]
  • [Cites] Clin Nucl Med. 2006 Dec;31(12):781-7 [17117072.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 May;32(5):549-56 [15599527.001]
  • (PMID = 19135929.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / 1 T32 EB001631-01; United States / NIBIB NIH HHS / EB / EB001631-01A1; United States / NIBIB NIH HHS / EB / T32 EB001631-01A1; United States / NIBIB NIH HHS / EB / T32 EB001631-02; United States / NIBIB NIH HHS / EB / T32 EB001631
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS125433; NLM/ PMC2743966
  •  go-up   go-down


73. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD: hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer; 2010 Sep 7;103(6):812-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer.
  • RESULTS: Cytoplasmic and/or membrane TF expression was observed in all 16 (100%) USPC samples tested by IHC, but not in normal endometrium.
  • High expression of TF was found in 50% (three out of six) of the USPC cell lines tested by real-time PCR and flow cytometry when compared with normal endometrial cells (NECs; P<0.001).
  • Uterine serous papillary adenocarcinoma cell lines overexpressing TF, regardless of their high or low HER2/neu expression, were highly sensitive to IDCC (mean killing+/-s.d., 65.6+/-3.7%, range 57.5-77.0%, P<0.001), although negligible cytotoxicity against USPC was seen in the absence of hI-con1 or in the presence of Rituximab control antibody.
  • The hI-con1 may represent a novel therapeutic agent for the treatment of patients harbouring advanced, recurrent and/or metastatic USPC refractory to standard treatment modalities.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1370-3 [16803532.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):139-44 [16182348.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902 [17009989.001]
  • [Cites] Ocul Immunol Inflamm. 2007 Jan-Feb;15(1):3-10 [17365800.001]
  • [Cites] Thromb Res. 2007;120 Suppl 2:S7-12 [18023716.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):3-9 [17945336.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):1-6 [18091328.001]
  • [Cites] Tissue Cell. 2008 Apr;40(2):95-102 [18031781.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Aug;102(2):128-31 [18555254.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):134-43 [19920829.001]
  • [Cites] Am J Pathol. 2010 Feb;176(2):1050-6 [20042667.001]
  • [Cites] Am J Obstet Gynecol. 2010 Aug;203(2):162.e1-8 [20417484.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1271-9 [12006548.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] J Clin Invest. 2000 Jul;106(1):117-24 [10880055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9221-5 [10922073.001]
  • [Cites] Thromb Haemost. 2001 Mar;85(3):379-89 [11307801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12180-5 [11593034.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C947-70 [11940508.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):181-5 [12821361.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):39-49 [14984766.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] J Immunol. 1987 May 15;138(10):3566-72 [2437198.001]
  • [Cites] Biochemistry. 1992 Apr 28;31(16):3998-4003 [1567850.001]
  • [Cites] Gynecol Oncol. 1992 Sep;46(3):317-21 [1526508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Nat Med. 1996 Feb;2(2):209-15 [8574967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14379-84 [8962059.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):63-70 [9815888.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):220-31 [10021305.001]
  • [Cites] J Virol. 1999 Jul;73(7):5402-10 [10364287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8161-6 [10393965.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8663-8 [10411932.001]
  • [Cites] Curr Opin Oncol. 1999 Sep;11(5):388-93 [10505777.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1734-41 [15494427.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):813-8 [15746676.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):24-30 [15894362.001]
  • [Cites] Thromb Haemost. 2005 Aug;94(2):444-53 [16113838.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1391-7 [16116605.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):494-9 [16894299.001]
  • (PMID = 20700124.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016359; United States / NCI NIH HHS / CA / R01 CA122728; United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / R01 CA122728-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 9001-25-6 / Factor VII
  • [Other-IDs] NLM/ PMC2966612
  •  go-up   go-down


74. Auranen A, Sundström J, Ijäs J, Grénman S: Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1011-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients had a simultaneous endometrial adenocarcinoma.
  • Recurrent disease was detected in seven patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374124.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  • [Number-of-references] 41
  •  go-up   go-down


75. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).
  • Additionally 37 primary and 12 recurrent breast carcinomas were detected by physical examination.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


76. Sengupta S, Church E, Chia KV: Sister Mary Joseph's nodule: recurrent endometrial adenocarcinoma presenting as an umbilical metastasis. J Obstet Gynaecol; 2009 Feb;29(2):170-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule: recurrent endometrial adenocarcinoma presenting as an umbilical metastasis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274568.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement